Oppenheimer analyst Owen Lau maintains Focus Finl Partners (NASDAQ:FOCS) with a Outperform and lowers the price target from $60 to $52.
AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and COVID-19 through PREPAiRE, an AI
